Table 1. Summary of phase I and II trials investigating impact of neoadjuvant chemoradiotherapy for locally advanced gastric cancer.

Trial (References)	N	Schedule	Number proceeding to surgery [%]	Post-operative mortality [%]	Pathological complete response [%]	Pathological complete or partial response [%]	R0 resection [%]
Lowy et al. [2001] (45)	24	5-FU, XRT, intraoperative XRT	19/24 [83]	5/19 [26]	2/24 [8]	NR	NR
Roth et al. [2003] (46)	19	Cisplatin, 5-FU, leucovorin, XRT	19/19 [100]	0	1/19 [5]	9/19 [47]	NR
Ajani et al. [2004] (42)	34	5-FU, leucovorin, cisplatin, XRT	28/33 [85]	2/28 [7]	10/34 [29]	18/34 [53]	23/34 [68]
Ajani et al. [2006] (43)	43	5-FU, leucovorin, cisplatin, XRT	36/43 [84]	0	11/43 [26]	NR	27/43 [63]
Wydmański et al. [2007] (47)	40	5-FU, leucovorin, XRT	32/40 [80]	NR	7/40 [18]	8/40 [20]	30/40 [75]
Inoue et al. [2012] (48)	12	S-1, XRT	12/12 [100]	0	2/12 [17]	10/12 [83]	11/12 [92]
Lee et al. [2012] (49)	12	S-1, oxaliplatin, XRT	12/12 [100]	0	1/12 [8]	6/12 [50]	11/12 [92]
Pera et al. [2012] (50)	41	Oxaliplatin, cisplatin, 5-FU	19/25 [76]	3/31 [10]*	3/25 [12]	11/25 [44]	29/41 [71]*
Trip et al. [2014] (44)	25	Carboplatin, paclitaxel, XRT	24/25 [96]	1/24 [4]	4/25 [16]	10/25 [40]	18/25 [72]

*, contained patients with both esophageal and gastric cancer. Outcomes other than mortality were reported individually; 5-FU, fluorouracil; XRT, radiotherapy; NR, not recorded.